Find a Clinical Trial

For many patients with difficult-to-treat cancers, the options have been few. Verastem Oncology aims to change that by pursuing RAS pathway-targeted treatment combinations with avutometinib (VS-6766). Find out more about our clinical trials here.

Verastem-Sponsored Trials Investigator-Sponsored Trials

A Study of Avutometinib (VS-6766) + Adagrasib in Patients with KRAS G12C-Mutated NSCLC

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Primary Condition

Non-Small Cell Lung Cancer


A Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib +/- Defactinib in Patients with KRAS G12C-Mutated NSCLC

This study will assess the safety and efficacy of avutometinib and sotorasib with or without defactinib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Primary Condition

Non-Small Cell Lung Cancer


A Study of Avutometinib (VS-6766) + Defactinib with Gemcitabine and Nab-Paclitaxel in Patients with Pancreatic Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Primary Condition

Pancreatic Cancer


A Study of Avutometinib (VS-6766) + Defactinib in Patients with KRAS G12C-Mutant, other KRAS and BRAF Mutated Recurrent Non-Small Cell Lung Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
Primary Condition

Non-Small Cell Lung Cancer


A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

This study will test if avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Primary Condition

Mesonephric Gynecologic Cancer


A Phase 2 Study of Avutometinib (VS-6766) + Defactinib in Patients with Gynecologic Cancers

The purpose of this research is to test the effectiveness and safety of the study drugs ((avutometinib (VS-6766) and defactinib)), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.
Primary Condition

Endometrioid Cancer


A Study of Avutometinib (VS-6766) and Cetuximab in Patients with Advanced Colorectal Cancer

Doctors leading this study hope to learn about the safety of combining the study drug avutometinib (VS-6766) with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.
Primary Condition

Colorectal Cancer


A Phase I/II Study of Avutometinib (VS-6766) + Abemaciclib + Fulvestrant in Patients with HR+/HER2-Negative Breast Cancer

This research is being done to evaluate the safety and effectiveness of a drug currently known as avutometinib (VS-6766) in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: VS-6766 Abemaciclib Fulvestrant
Primary Condition

Breast Cancer


A Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody.
Primary Condition

Pancreatic Cancer


A Phase I Study of Avutometinib (VS-6766) + Defactinib in Patients with Advanced Solid Tumors

This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, avutometinib (VS-6766) in patients with advanced solid tumours. VS-6766 (RO5126766) is the same compound as CH5126766.
Primary Condition

Low-Grade Serous Ovarian Cancer


A Phase I Trial of Avutometinib (VS-6766) monotherapy and in Combination with Everolimus in Patients with BRAF, KRAS and NRAS-Mutant Solid Tumors

In Part I of the study avutometinib (VS-6766) will be given twice weekly or three times per week in treatment cycles of 4 weeks to investigate a safe and tolerable dose of the drug. Once the optimal dosing schedule is defined, the following patients with BRAF, KRAS and/or NRAS mutations will be enrolled: 26 patients with solid tumours (Parts IIA & IIC) and 10 patients with Multiple Myeloma (Part IIB). Up to 44 patients with solid tumours containing BRAF, KRAS and/or NRAS mutations will take VS-6766 in combination with everolimus (Part IID). Of these, 20 patients will comprise the Part IID dose expansion and will all have KRAS-mutant lung cancer.
Primary Condition

Lung Cancer


A Phase 3 Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Primary Condition

Low-Grade Serous Ovarian Cancer